Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Jinsheng, Ding"'
Autor:
Danqi Fu, Jingrui Yan, Zhaoyu Zhang, Yang Liu, Xiaoqing Ma, Jinsheng Ding, Shengyu Yang, Ran Zhao, Antao Chang, Chuntao Gao, Jing Liu, Tiansuo Zhao, Xiuchao Wang, Chongbiao Huang, Song Gao, Ying Ma, Bo Tang, Yukuan Feng, Hongwei Wang, Jihui Hao
Publikováno v:
Cancer Biology & Medicine, Vol 20, Iss 8, Pp 599-626 (2023)
Objective: Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant gastrointestinal cancer with a 5-year survival rate of only 9%. Of PDAC patients, 15%-20% are eligible for radical surgery. Gemcitabine is an important chemotherapeutic agent fo
Externí odkaz:
https://doaj.org/article/a41f4acb910649a6b6434c404baaece3
Autor:
Yongjie Xie, Yang Liu, Jinsheng Ding, Guangming Li, Bo Ni, Huifang Pang, Xin Hu, Liangliang Wu
Publikováno v:
Frontiers in Cell and Developmental Biology, Vol 10 (2022)
Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignant tumors worldwide and has poor prognosis. DEAD box proteins31 (DDX31) participate in cellular processes involving RNA secondary structure changes. However, the funct
Externí odkaz:
https://doaj.org/article/0a5e12ddd65e4178aa62d7738f7c6ae3
Autor:
Jinsheng Ding, Hui Li, Yang Liu, Yongjie Xie, Jie Yu, Huizhi Sun, Di Xiao, Yizhang Zhou, Li Bao, Hongwei Wang, Chuntao Gao
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is a type of malignant tumor with a five-year survival rate of less than 10%. Gemcitabine (GEM) is the most commonly used drug for PDAC chemotherapy. However, a vast majority of patients with PDAC dev
Externí odkaz:
https://doaj.org/article/948f63ba82084a768da6ea5f421b1b8d
Autor:
Yongjie, Xie, Yang, Liu, Jinsheng, Ding, Guangming, Li, Bo, Ni, Huifang, Pang, Xin, Hu, Liangliang, Wu
Publikováno v:
Frontiers in cell and developmental biology. 10
Purpose: Pancreatic cancer is one of the most malignant cancers with rapid disease progression. Pancreatic ductal adenocarcinoma (PDAC) accounts for more than 90% in exocrine pancreatic cancer. DDX31 is one of the Asp-Glu-Ala-Asp (DEAD)-box RNA helic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::15f61e07d0ca9bdf351f25366f8942f2
https://doi.org/10.21203/rs.3.rs-520114/v1
https://doi.org/10.21203/rs.3.rs-520114/v1